Research Article

Study of Inflammatory and Infection Markers in Periprosthetic Fluid: Correlation with Blood Analysis in Retrospective and Prospective Studies

Andrea Lisa,1 Cristina Belgiovine,1,2 Luca Maione,1,3 Andrea Rimondo,1 Andrea Battistini,1 Benedetta Agnelli,4 Matteo Murolo,1 Leonardo Galtelli,1 Marta Monari,5 Marco Klinger,6 and Valeriano Vinci1,4

1Humanitas Clinical and Research Center-IRCCS, Via Manzoni 56, 20089 Rozzano Milan, Italy
2Scuola di Specializzazione in Microbiologia e Virologia, Università degli Studi di Pavia, 27100 Pavia, Italy
3University of Milan, Reconstructive and Aesthetic Plastic Surgery School-Clinica San Carlo-Plastic Surgery Unit-Paderno Dugnano (Milan), Italy
4Humanitas University Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy
5Clinical Investigation Laboratory, Humanitas Clinical and Research Center, Via Alessandro Manzoni 56 20089 Rozzano Milano, Italy
6Plastic Surgery Unit, Department of Medical Biotechnology and Translational Medicine BIOMETRA, Humanitas Clinical and Research Hospital, Reconstructive and Aesthetic Plastic Surgery School, University of Milan, Via Manzoni 56, Rozzano, Milan 20090, Italy

Correspondence should be addressed to Andrea Lisa; andrealisamd@gmail.com

Received 8 December 2020; Revised 25 February 2021; Accepted 8 March 2021; Published 19 March 2021

Academic Editor: Nor Ainy Mahyudin

Copyright © 2021 Andrea Lisa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Surgical site infection represents the most severe complication in prosthetic breast reconstruction. Risk profiling represents a useful tool for both clinicians and patients. Materials and Methods. In our hospital, 534 breast reconstructions with tissue expander implants, in 500 patients, were performed. Several clinical variables were collected. In our study, we evaluated the different inflammatory markers present in the periprosthetic fluid and we compared them with the ones present in plasma. Results. The surgical site infection rate resulted to be 10.5%, and reconstruction failed in 4.5% of the cases. The hazard ratio for complications was 2.3 in women over 60 (CI: 1.3-4.07; \( p = 0.004 \)), 2.57 in patients with expander volume \( \geq 500 \text{ cc} \) (CI: 1.51-4.38; \( p < 0.001 \)), 2.14 in patients submitted to previous radiotherapy (CI: 1.05-4.36; \( p < 0.037 \)), and 1.05 in prolonged drain use (CI: 1.03-1.07; \( p = 0.001 \)). 25-OH, PCT, and total protein were less concentrated, and ferritin and LDH were more concentrated in the periprosthetic fluid than in plasma (\( p < 0.001 \)). CRP (\( p = 0.190 \)) and \( \beta-2 \) microglobulin (\( p = 0.344 \)) did not change in the two fluids analyzed. PCT initial value is higher in patients who underwent radiotherapy, and it could be related to the higher rate of their postoperative complications. Patients with a tissue expander with a volume \( \geq 500 \text{ cc} \) show an increasing trend for CRP in time (\( p = 0.009 \)). Conclusions. Several risk factors in the periprosthetic fluid with respect to their study in plasma could point toward earlier infection detection and support early management.

1. Introduction

Breast cancer is the most common cancer among women worldwide [1], and it represents around 29% of all cancers in Italian women [2, 3]. The progressive increase in the diagnosis of breast cancer determines a simultaneous increase in the rate of postmastectomy breast reconstructions. For both simplicity and lack of donor site morbidity, prosthetic reconstruction is
commonly adopted. Moreover, compared with autologous breast reconstruction, it presents shorter surgical time, decreased hospitalization, and quicker recovery [4, 5].

However, this surgery is not risk-free; early or late infections, wound dehiscence, or mastectomy skin flap necrosis may present. The most severe is surgical site infection which can lead to reconstructive failure and, in the worst cases, removal of the implant [6]. Infection rates following prosthetic breast reconstruction are reported. The latter are linked to several risk factors like previous chemotherapy and/or radiotherapy, smoking, higher BMI, larger breast size, and lymph node dissection [7–10], ranging from 1 to 35% [11, 12]. At the moment, no biochemical marker is able to provide an early detection of the local inflammatory state and to predict the risk of early or late postsurgical complications.

The periprosthetic fluid, which accumulates in the drains, is a waste fluid easily collected. It should be considered both a mirror of the processes occurring inside the pocket during the early postoperative period and a potential cause of local inflammation, being a direct connection with the external environment.

A longer time to drain removal is associated with an increased rate of infection [13], although little is known about drainage fluid: its origin, its biochemical composition, and its differences in patients with a regular postoperative course and in patients presenting complications. Either this fluid could derive from blood filtration or it may be a wound exudate that develops in the inflammatory phase of wound healing [14].

For the aforementioned reasons, we performed a retrospective study of 500 patients (534 prosthetic reconstruction) to analyze risk factors for infection. Moreover, we prospectively analyze drainage fluid to characterize it from a biochemical point of view.

2. Methods
2.1. Patient Selection. We conducted a retrospective analysis, IRB-approved, on patients who underwent unilateral/bilateral immediate postmastectomy tissue expander breast reconstruction at Humanitas Research Hospital from January 2013 to December 2016. Moreover, we performed a prospective analysis on 32 patients who underwent mastectomy and one-stage breast reconstruction at Humanitas Research Hospital between November 2016 and May 2017.

Demographic, reconstructive, and complication data were obtained from medical records and collected into a clinical database.

“Smokers” were defined as patients who continued to smoke throughout the perioperative period and/or those who stopped less than 4 weeks preoperatively. “Ex-smokers” are defined as patients who had stopped smoking between 1 and 12 months preoperatively. We have considered both groups as a single group since it has been observed that complication rates are similar in these two populations [10]. Patients were considered to have undergone neoadjuvant chemotherapy if they completed therapy within 6 weeks from mastectomy and subsequent reconstruction.

Surgical technique (total, nipple-sparing, and skin-sparing mastectomy), operative time, sentinel lymph node biopsy with or without axillary dissection, and expander brand and volume were also collected.

Infection was clinically defined considering the following signs or symptoms: fever (>38°), localized erythema, swelling, pain, wound dehiscence, expander exposure, and purulent drainage from deep incisions.

The cutoff between early and late infections was considered to be 30 days.

2.2. Surgical Technique. We performed first-stage breast reconstruction with a tissue expander or single-stage breast reconstruction with a definitive prosthesis, depending on breast characteristics, mastectomy type, intraoperative conditions, tissues’ quality, and indication for subsequent radiotherapy. Closed drainage suction systems were placed in the subcutaneous tissue, in the periprosthetic pocket and, if axillary lymph node dissection was performed, also in the axilla. All tissue expander reconstructions were performed using anatomic and textured expanders with an integrated expansion port from either Mentor (Mentor Corporation, Santa Barbara, Calif.) or Allergan (Allergan Corporation, Marlow International, Parkway, Marlow, Bucks, SL7 1 YL, United Kingdom). No acellular dermal matrix (ADM) has ever been employed in the selected patients. Expanders were placed in a complete submuscular position and filled intraoperatively with a variable amount of saline. A reduced filling volume is indicated in smokers and patients submitted to previous radiotherapy (never more than 10% of overall volume). At complete wound healing, saline instillations started in the outpatient setting, and then, they were performed every two weeks. If radiotherapy was required for oncological reasons, expansions were interrupted and restarted 2-3 months after the last session of radiotherapy, according to skin conditions. The duration of hospitalization was around 1-3 nights. The compressive dressing placed after surgery was removed at the first consultation in the outpatient setting. Antibiotic prophylaxis consisted of cefazolin 2g iv. Intraperatively, all patients received intravenous antibiotics, prolonged orally (cefazolin 1 g once a day) in the postoperative period until drain removal. Acetaminophen was prescribed as an analgesic therapy.

2.3. Postoperative Procedure and Periprosthetic Fluid Collection. The first consultation was planned 5 days postoperatively. The second consultation was planned about a week after. The following consultations were planned every week for the first month and then every 2-3 weeks, unless complications occurred. The drainage tubes were removed when the drained fluid was steadily less than 50 mL per day for a 3-day period. Whenever possible, fluid was collected from the drainage system into an EDTA and a serum test tube on the 1st postoperative day and at following outpatient consultations, and it was sent to the laboratory. Only patients from whom the drainage fluid was collected on the 1st postoperative day and at least another time (first or second outpatient consultations) were included in the study. The timing of the drainage collection is shown in Table 1.
2.4. Measure of Biological Markers. We analyzed the following parameters, considering their wide availability in the clinical routine as inflammatory markers and their moderate cost: 25-hydroxyvitamin D (25-OH), procalcitonin (PCT), ferritin, total protein, lactate dehydrogenase (LDH), C-reactive protein (CRP), and β-2 microglobulin. 25-OH was analyzed using the LIASON® 25 OH Vitamin D Assay, which is a direct and competitive immunological test, resting on the Chemiluminescence Immunoassay based on recombinant ViSE (CLIA) principle. The LIASON® BRAHMS PCT® II GEN test takes advantage of the CLIA principle in order to quantify PCT. ARCHITECT Ferritin is the Chemiluminescent Microparticle Immunoassay (CMIA) applied for the analysis of ferritin. Total protein was quantified through the ARCHITECT cSystems. The ARCHITECT Lactate Dehydrogenase 2P56 kit was applied to determine the dosage of LDH. ARCHITECT cSystems MULTIGENT CRP16 was used for the quantitative immunoturbidimetric determination of CRP. β-2 microglobulin was analyzed through the Abbott ARCHITECT cSystems.

2.5. Statistical Analysis. For the retrospective analysis, we used a proportional hazard Cox regression analysis. Factors with a significance level at univariable analysis under 0.1 were then submitted to a multivariable Cox regression analysis. Among the patients who had developed infection, the presence of possible risk factors for the explant was evaluated through logistic regression analysis. A p value less than 0.05 was considered significant. The analysis was carried out with Stata 13. For the prospective analysis, we explored different methods: Mann-Whitney test and paired t-test, and we performed a multivariable analysis. Statistical significance was set at p = 0.05. Chi-square or Fisher’s exact test was used when indicated. Statistical analysis was performed with SPSS software (version 21.0; IBM Corporation, Armonk, NY).

3. Results

3.1. Risk Factors for Breast Reconstruction Failure: Retrospective Study. Over the 3-year study period, 534 consecutive tissue expander reconstructions were performed in 500 patients (Table 2). The overall surgical site infection (SSI) rate was 10.49% (56 out of 534, 95% CI: 8.02%–13.40%) among which 55.36% were early infection (31 out of 56) while 44.64% occurred after 30 days from the operation (late infections). Reconstructive failure, defined as explander removal, occurred in 24 patients (4.49% of the total sample and 42.86% of those who developed SSI). Reconstructive failure was determined by late infections in 54.17% of cases (13 patients out of 24).

In order to identify infection risk factors, we performed a univariable and multivariable statistical analysis (results in Table 3). Univariable analysis was also performed to identify risk factors for reconstructive failure in the group of patients who developed SSI, although we did not identify any risk factor (Table 4).

3.2. Prospective Study: Cohort Description. The main characteristics of the 32 patients are presented in Table 5.

3.3. Biological Marker of Infection: Plasma versus Periprosthetic Fluid. A preliminary analysis was performed comparing the fluids collected from the first patients using both EDTA and serum test tubes, showing that, on 77 parameter trends considered, 9 (12%) differences were recorded. Among the latter, 5 and 4 cases showed increasing trends with serum and with the EDTA test tube, respectively. Six differences were recorded in LDH, two in 25-OH, and one in β-2 microglobulin. All the remaining analyses were performed only using serum test tubes.

Time 0 collection was analyzed in order to investigate the range of variability of the parameters and therefore the cutoff that we used to define the stability of each parameter in time. The results are presented in Table 6. The comparison of the distribution of the parameters between the periprosthetic fluid and the referred reference interval in plasma is presented in Table 7 (chi-square or Fisher’s exact test was used when indicated). The only variables whose distributions did not differ from the plasmatic ones were CRP (p = 0.190) and β-2 microglobulin (p = 0.344). 25-OH, PCT, and total protein were less concentrated in the periprosthetic fluid than in plasma (p < 0.001), whereas
Table 3: Hazard ratios for risk factors.

| Risk Factor                          | Univariable HR (95% CI) | Univariable p | Multivariable HR (95% CI) | Multivariable p |
|--------------------------------------|--------------------------|---------------|---------------------------|-----------------|
| Age                                  | 1.04 (1.02–1.06)         | 0.001         | 1.03 (1.00–1.06)          | 0.032           |
| Age (>60 years)                      | 2.30 (1.30–4.07)         | 0.004         |                           |                 |
| BMI                                  | 1.04 (0.98–1.09)         | 0.183         |                           |                 |
| BMI (>30)                            | 1.60 (0.76–3.38)         | 0.220         |                           |                 |
| Smoke (active + ex)                  | 1.37 (0.79–2.36)         | 0.261         |                           |                 |
| Diabetes                             | 1.31 (0.32–5.35)         | 0.712         |                           |                 |
| Autoimmune pathologies               | 1.49 (0.60–3.74)         | 0.394         |                           |                 |
| Chemotherapy                         | 0.77 (0.46–1.31)         | 0.337         |                           |                 |
| Neoadjuvant chemotherapy             | 0.37 (0.12–1.18)         | 0.092         |                           |                 |
| Adjuvant chemotherapy                | 1.02 (0.60–1.72)         | 0.954         |                           |                 |
| Previous RT                          | 2.14 (1.05–4.36)         | 0.037         |                           | 0.068           |
| Expander brand (Mentor)              | 1.17 (0.66–2.07)         | 0.582         |                           |                 |
| Expander volume (>500 mL)            | 2.57 (1.51–4.38)         | 0.001         | 2.02 (1.12–3.65)          | 0.019           |
| Axillary dissection                  | 0.83 (0.49–1.41)         | 0.486         |                           |                 |
| Bilateral                            | 0.80 (0.25–2.56)         | 0.708         |                           |                 |
| Mstec (×10 minutes)                  | 0.99 (0.93–1.06)         | 0.854         |                           |                 |
| RMI                                  | 0.99 (0.98–1.01)         | 0.283         |                           |                 |
| Total duration (×10 minutes)         | 0.99 (0.94–1.04)         | 0.647         |                           |                 |
| Time of drainage (days)              | 1.05 (1.03–1.07)         | <0.001        | 1.03 (1.01–1.06)          | 0.014           |

Table 4: Risk factors for reconstruction failure in SSI patients.

| Risk Factor                          | Yes     | No     | p      | OR (95% CI) | p      |
|--------------------------------------|---------|--------|--------|-------------|--------|
| N                                    | 24      | 32     |        |             |        |
| Age (years)                          | 54 ± 12 | 56 ± 12| 0.481  | 0.99 (0.95–1.03) | 0.619 |
| Age (>60 years)                      | 8 (33.33%) | 9 (28.13%) | 0.772 | 1.28 (0.41–4.02) | 0.675 |
| BMI                                  | 25.6 ± 4.7 | 24.7 ± 5.2 | 0.230 | 1.04 (0.93–1.15) | 0.527 |
| BMI (>30)                            | 4 (16.67%) | 4 (12.90%) | 0.718 | 1.35 (0.30–6.06) | 0.695 |
| Smoke (active + ex)                  | 12 (50.00%) | 8 (25.00%) | 0.090 | 3.00 (0.97–9.30) | 0.057 |
| Diabetes                             | 2 (8.33%) | 0      | 0.179  | 1           |        |
| Autoimmune pathologies               | 3 (12.50%) | 2 (6.25%) | 0.642 | 2.14 (0.33–13.96) | 0.425 |
| Chemotherapy                         | 11 (45.83%) | 16 (50.00%) | 0.793 | 0.85 (0.29–2.44) | 0.758 |
| Neoadjuvant chemotherapy             | 0       | 3 (9.38%) | 0.252  | 1           |        |
| Adjuvant chemotherapy                | 11 (45.83%) | 13 (40.63%) | 0.788 | 1.24 (0.42–3.60) | 0.697 |
| Previous RT                          | 2 (8.33%) | 7 (21.88%) | 0.274 | 0.32 (0.06–1.73) | 0.187 |
| RT                                   | 5 (20.83%) | 8 (25.00%) | 0.760 | 0.79 (0.22–2.81) | 0.715 |
| Expander brand (Mentor)              | 9 (37.50%) | 8 (25.00%) | 0.384 | 1.80 (0.57–5.69) | 0.317 |
| Expander volume (>500 mL)            | 11 (45.83%) | 12 (37.50%) | 0.590 | 1.41 (0.48–4.13) | 0.531 |
| Axillary dissection                  | 11 (45.83%) | 13 (40.63%) | 0.788 | 1.24 (0.42–3.60) | 0.697 |
| Bilateral                            | 2 (8.33%) | 1 (3.13%) | 0.571 | 2.82 (0.24–33.05) | 0.409 |
| Mstec (×10)                          | 9.81 ± 3.80 | 7.93 ± 3.10 | 0.091 | 1.18 (0.99–1.42) | 0.071 |
| RMI                                  | 58.2 ± 19.8 | 59.8 ± 13.9 | 0.481 | 0.99 (0.96–1.03) | 0.716 |
| Total duration (×10)                 | 15.63 ± 5.19 | 13.92 ± 3.07 | 0.344 | 1.12 (0.96–1.30) | 0.158 |
Table 5: Patients’ characteristics.

| Characteristics                  | n = 32 |
|----------------------------------|--------|
| Bilateral intervention           | 3 (9%) |
| Median age (range)               | 52 (32-69) |
| Median BMI (range)               | 22.9 (17.4-33.4) |
| Current smoker                   | 9 (28%) |
| Previous breast surgery          | 11 (34%) |
| Previous RT                      | 8 (25%) |
| Previous CT                      | 5 (16%) |
| Prophylactic mastectomy          | 4 (13%) |
| Demolitive surgery               |        |
| Radical mastectomy               | 10 (31%) |
| Nipple-sparing mastectomy        | 19 (59%) |
| Skin-sparing mastectomy          | 3 (9%)  |
| Implant type                     |        |
| Expander                         | 27 (84%) |
| Immediate prosthesis             | 5 (16%) |
| Median implant size (cc) (range) | 400 (125-650) |
| Median prefilling expander volume (cc) (range) | 100 (20-400) |
| Operated side                    |        |
| Bilateral                        | 3 (9%)  |
| Right                            | 14 (44%) |
| Left                             | 15 (47%) |
| Contralateral intervention       | 2 (6%)  |
| Axillary dissection              | 6 (19%) |

Table 6: Range of variability of the parameters and cutoff for stability adopted.

| Parameter       | Unit    | Min   | Max   | Ratio max/min | Cutoff for stability |
|-----------------|---------|-------|-------|---------------|----------------------|
| 25-OH           | ng/mL   | <4.0  | 39.5  | 10            | 1/2 or ×2            |
| PCT             | ng/mL   | <0.02 | 3.71  | 185           | 1/3 or ×3            |
| Ferritin        | ng/mL   | 71    | 2910  | 41            | 1/3 or ×3            |
| LDH             | IU/L    | 974   | >6650 | 7             | 1/2 or ×2            |
| Total protein   | g/L     | 20.3  | 85.7  | 4             | 1/2 or ×2            |
| CRP             | mg/dL   | 0.03  | 1.10  | 37            | 1/3 or ×3            |
| β-2 microglobulin | mg/L   | <0.25 | 2.93  | 12            | 1/2 or ×2            |

ferritin and LDH were more concentrated in the periprosthetic fluid than in plasma (p < 0.001).

The distributions of PCT and CRP in periprosthetic fluid and plasma are shown in Figure 1.

3.4. CRP as a Marker of Early Infection. We categorized the trends for each parameter during fluid collection (between the last and the first), and they are reported in Table 8. 25-OH showed a stable trend in 25 (78%) patients, with only 6 (19%) patients presenting increasing values in time. PCT was stable in 15 (47%), decreasing in 7 (22%), and increasing in 10 (31%) patients. Ferritin was higher at the last collection with respect to the first one in 20 patients (63%) and stable in 11 patients (34%). LDH tended to decrease in 24 patients (75%) and remained constant in 8 patients (25%). Total protein was stable in 28 (88%) patients, with only 4 (13%) showing a decreasing trend. CRP was stable in 17 (53%), decreasing in 5 (16%), and increasing in 10 (31%) patients. Eventually, most patients (94%) had an increasing trend of β-2 microglobulin in time.

We focused our attention on CRP. CRP is the only parameter that is concentrated in a similar manner in blood as well as in drainage fluid and analyzable trends. Also, β-2 microglobulin has shown a similar distribution in plasma and in periprosthetic fluid; however, 94% of patients had an increasing trend; therefore, it could not be investigated. We analyzed the correlations between patients and surgery characteristics and an increasing trend for CRP in time in the periprosthetic fluid. Patients with a tissue expander with a volume ≥ 500 cc had a higher probability of showing an increasing trend for CRP in time (OR = 21.600, 95%CI = 2.135–218.579, p = 0.009), and this was the only factor which tested statistically significant in univariate analysis (Table 9).

Patients with a BMI > 23 showed an increasing trend of CRP in time (OR = 4.083, 95%CI = 0.818–20.376, p = 0.086).

4. Discussion

Breast reconstruction has been shown to improve postmastectomy quality of life, to aid in coping with the diagnosis of breast cancer, and to decrease psychologic morbidity [10, 15, 16]. Tissue expander/prosthesis reconstruction is a well-established technique which can provide excellent aesthetic results although surgical site infection still represents the highest predictive factor of subsequent implant failure [17].

A successful reconstruction starts with careful patient selection and meticulous preoperative planning. Several studies have attempted to identify risk factors for complications following prosthetic breast reconstruction [6–12].

Our study firstly provides data about 534 consecutive tissue expander/implant reconstructions in 500 women evaluating the impact of clinical risk factors on the development of local infection. Secondly, we conducted a preliminary prospective analysis of 32 patients who underwent mastectomy and implant-based breast reconstructive surgery aimed at investigating the microenvironment of the fluid collected in the periprosthetic pocket drainage system.

Previous studies about this topic reported different features as markers of early detection of infection leading to possible implant loss: obesity [18–22], smoking [17–19, 22], hypertension [17, 19], chemotherapy [23] and radiotherapy [24], age [17, 19, 23], drainage maintenance [13], and also volume of the tissue expander [18].

In our work, the main predictive factor is represented by expander volume. This variable is directly related to breast volume since we select it according to the patient’s anatomic features. We are convinced that the main cause of local infection in these patients is related to delayed seroma. The latter may be determined either by increased fluid in the periprosthetic space, which indeed appears to be greater in these patients, or by a reduced vascularization of the mastectomy flap in bigger breasts. This data is confirmed also by the
prospective analysis in which we found that patients with a tissue expander with a volume $\geq 500$ cc had a higher probability of showing an increasing trend for CRP in time ($p = 0.009$). Breast weight represents an interesting variable to consider together with expander volume. Actually, this parameter is missing in our clinical database, but we will introduce it in future research.

It has been demonstrated, also in previously published reports, that the administration of neoadjuvant or adjuvant chemotherapy does not affect the risk of complications. On the other hand, radiotherapy needs a more complex analysis. Indeed, we found that a history of irradiation increases the risk for the development of local infection. Our group does not consider this condition as a relative adverse indication [25]. Indeed, if we observe the OR of reconstruction failure previous radiation, it appears to be inferior to 1, although without statistical significance. In our opinion, this observation is due to the fact that previously irradiated patients are more strictly evaluated for the known risk of local infection and in a certain amount of patients we actually consider local infection as redness related to previous radiodamage. Moreover, these patients, analyzed in the prospective study, showed an increased probability of having a higher initial value of PCT ($p = 0.033$).

Interestingly, as already observed by Power et al. [13], we detected a statistically significant correlation between time of drainage maintenance and development of local infections. In particular, if we set a cutoff of 21 days, we observed a statistical significant increase in local infections. As already declared, it is possible that prolonged fluid production determines a delayed healing and that the drains could act as a direct conduit from the external environment into the peri-prosthetic space.

For this reason, we agree that for a period of drainage maintenance greater than 3 weeks, the risk of maintaining the drain outweighs the risk of fluid collection.

The main aim of our small cohort of prospective analysis was to investigate the composition of the periprosthetic fluid in order to elucidate the possible role of the different inflammatory parameters both in the process of capsule formation and in the risk of development of postoperative complications. First of all, analyzing inflammatory markers, we found that the microenvironment of the periprosthetic fluid presents a different composition with respect to plasma. This could mean that not only is the periprosthetic fluid composed of extravasated blood but also it could represent a particular microenvironment in which inflammatory processes occur immediately after surgery, since the differences with plasma were evident since the first postoperative day. In

### Table 7: The comparison of the distribution of the parameters between the periprosthetic fluid and the plasmatic referred reference interval (chi-square or Fisher’s exact test was used when indicated).

| Parameter | Unit           | Plasmatic reference interval | Median value in fluid | Fluid values < min plasma | Fluid values > max plasma | $p$ value |
|-----------|----------------|------------------------------|------------------------|---------------------------|---------------------------|-----------|
| 25-OH     | ng/mL          | 30.0-100.0                   | 18.5                   | 26 (81%)                  | /                         | <0.001    |
| PCT       | ng/mL          | 0.00-0.50                    | 0.04                   | /                         | 3 (9%)                    | <0.001    |
| Ferritin  | ng/mL          | 20-250                       | 346                    | /                         | 22 (69%)                  | <0.001    |
| LDH       | IU/L           | 125-243                      | 3791                   | /                         | 32 (100%)                 | <0.001    |
| Total protein | g/L | 60.0-80.0                   | 46.3                   | 26 (81%)                  | 1 (3%)                    | <0.001    |
| CRP       | mg/dL          | 0.01-0.50                    | 0.17                   | /                         | 4 (13%)                   | 0.190     |
| $\beta-2$ microglobulin | mg/L | 0.97-2.64                    | 1.60                   | /                         | 1 (3%)                    | 0.344     |

**Figure 1:** (a) PCT is less concentrated in the periprosthetic fluid than in plasma ($p < 0.001$). (b) CRP shows a similar distribution between periprosthetic fluid and plasma ($p = 0.190$).
particular, 25-OH, PCT, and total protein were less concentrated in the periprosthetic fluid than in plasma, whereas ferritin and LDH were more concentrated in the periprosthetic fluid \( (p < 0.001) \). The only parameters whose distribution did not differ from the plasmatic ones were CRP \( (p = 0.190) \) and \( \beta-2 \) microglobulin \( (p = 0.344) \).

These data could allow an improvement in our clinical practice: on the one hand, this work represents one of the largest single-center European report, and on the other hand, from the analysis of our results, we aim to obtain valuable information on the association between clinical variables and outcomes in our specific population.
Furthermore, our preliminary study showed that the composition of drainage microenvironment following mastectomy and implant-based breast reconstruction is different from the plasmatic one in terms of inflammatory parameters. This data suggests that the fluid could represent the expression of a complex local inflammatory process. Moreover, the values of PCT and CRP in the periprosthetic fluid, found, respectively, in patients who had undergone previous radiotherapy and patients with a tissue expander with a volume $\geq 500$ cc, could be potentially related to a higher risk of developing infectious complications. These findings could allow us to identify value cutoffs for inflammatory parameters at specified postsurgical times able to predict an increased risk for postoperative complications, and they could allow a better tailoring of the postoperative antibiotic prophylaxis, as specific subsets of patients could be addressed to a more aggressive prophylaxis, whenever risk factors for infection were recognized based on the periprosthetic fluid collection during the first outpatient consultation. Further studies are needed in order to confirm the preliminary results and to better investigate the periprosthetic microenvironment, including other inflammatory parameters such as TNF-$\alpha$, IL-1, IL-6, TGF-$\beta$, and pentraxin with special attention to potential correlations with the clinical outcomes. Another point to strengthen our analysis is suggested by Stewart et al. who performed the count of neutrophils present in the periprosthetic space to discover infections [25]. Moreover, a larger sample of patients should be included, in order to analyze possible correlations between the composition of the fluid and the clinical outcomes of the reconstructions, which could be possible only when a sufficient number of infectious complications will be recorded, considering their relatively low incidence rate.

**Data Availability**

Data are available on request.

**Ethical Approval**

The principles outlined in the Declaration of Helsinki have been followed in this study.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest to disclose.

**References**

[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” *CA: a Cancer Journal for Clinicians*, vol. 61, no. 2, pp. 69–90, 2011.

[2] E. Grande, R. Inghelmann, S. Francisci et al., “Regional estimates of breast cancer burden in Italy,” *Tumori*, vol. 93, no. 4, pp. 374–379, 2007.

[3] L. C. Argenta, “Reconstruction of the breast by tissue expansion,” *Clinics in Plastic Surgery*, vol. 11, no. 2, pp. 257–264, 1984.

[4] N. Shaikh-Naidu, B. A. Preminger, K. Rogers, P. Messina, and L. B. Gayle, “Determinants of aesthetic satisfaction following TRAM and implant breast reconstruction,” *Annals of Plastic Surgery*, vol. 52, no. 5, pp. 465–470, 2004.

[5] M. C. McCullough, C. K. Chu, C. S. Duggal, A. Losken, and G. W. Carlson, “Antibiotic prophylaxis and resistance in surgical site infection after immediate tissue expander reconstruction of the breast,” *Annals of Plastic Surgery*, vol. 77, no. 5, pp. 501–505, 2016.

[6] D. Saha, A. A. Davila, J. P. ver Halen et al., “Post-mastectomy reconstruction: a risk-stratified comparative analysis of outcomes,” *Breast*, vol. 22, no. 6, pp. 1072–1080, 2013.

[7] M. Y. Nahabedian, T. Tsangaris, B. Momen, and P. N. Manson, “Infectious complications following breast reconstruction with expanders and implants,” *Plastic and Reconstructive Surgery*, vol. 112, no. 2, pp. 467–476, 2003.

[8] J. P. Fischer, A. M. Wes, C. T. Tuggle III, J. M. Serletti, and L. C. Wu, “Risk analysis of early implant loss after immediate breast reconstruction: a review of 14,585 patients,” *Journal of the American College of Surgeons*, vol. 217, no. 6, pp. 983–990, 2013.

[9] J. P. Fischer, J. A. Nelson, A. Au, T. CT III, J. M. Serletti, and L. C. Wu, “Complications and morbidity following breast reconstruction—a review of 16,063 cases from the 2005-2010 NSQIP datasets,” *Journal of Plastic Surgery and Hand Surgery*, vol. 48, no. 2, pp. 104–114, 2013.

[10] V. Gebski, M. Lagleva, A. Keech, J. Simes, and A. O. Langlands, “Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective,” *Journal of the National Cancer Institute*, vol. 98, no. 1, pp. 26–38, 2006.

[11] L. L. Washer and K. Gutowski, “Breast implant infections,” *Infectious Disease Clinics of North America*, vol. 26, no. 1, pp. 111–125, 2012.

[12] K. R. Hanna, A. Tilt, M. Holland et al., “Reducing infectious complications in implant based breast reconstruction,” *Annals of Plastic Surgery*, vol. 76, Supplement 4, pp. S312–S315, 2016.

[13] G. Power, Z. Moore, and T. O’Connor, “Measurement of pH, exudate composition and temperature in wound healing: a systematic review,” *Journal of Wound Care*, vol. 26, no. 7, pp. 381–397, 2017.

[14] J. P. Fischer, J. A. Nelson, J. M. Serletti, and L. C. Wu, “Perioperative risk factors associated with early tissue expander (TE) loss following immediate breast reconstruction (IBR): a review of 9305 patients from the 2005-2010 ACS-NSQIP datasets,” *Journal of Plastic, Reconstructive & Aesthetic Surgery*, vol. 66, no. 11, pp. 1504–1512, 2013.

[15] J. D. Wink, J. P. Fischer, J. A. Nelson, J. M. Serletti, and L. C. Wu, “Direct-to-implant breast reconstruction: an analysis of 1612 cases from the ACS-NSQIP surgical outcomes database,” *Journal of Plastic Surgery and Hand Surgery*, vol. 48, no. 6, pp. 375–381, 2014.

[16] C. M. McCarthy, B. J. Mehrara, E. Riedel et al., “Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk,” *Plastic and Reconstructive Surgery*, vol. 121, no. 6, pp. 1886–1892, 2008.

[17] J. D. Watson, J. R. C. Sainsbury, and J. M. Dixon, “ABC of breast diseases. Breast reconstruction after surgery,” *BMJ*, vol. 310, no. 6972, pp. 117–121, 1995.

[18] A. Edsander-Nord, Y. Brandberg, and M. Wickman, “Quality of life, patients’ satisfaction, and aesthetic outcome after...
pedicled or free TRAM flap breast surgery,” Plastic and Recon-structive Surgery, vol. 107, no. 5, pp. 1142–1153, 2001.

[19] W. N. Andrade, N. Baxter, and J. L. Semple, “Clinical determinants of patient satisfaction with breast reconstruction,” Plastic and Reconstructive Surgery, vol. 107, no. 1, pp. 46–54, 2001.

[20] E. A. Krueger, E. G. Wilkins, M. Strawderman et al., “Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy,” International Journal of Radiation Oncology • Biology • Physics, vol. 49, no. 3, pp. 713–721, 2001.

[21] L. A. Woerdeman, J. J. Hage, M. M. I. Hofland, and E. J. T. Rutgers, “A prospective assessment of surgical risk factors in 400 cases of skin-sparing mastectomy and immediate breast reconstruction with implants to establish selection criteria,” Plastic and Reconstructive Surgery, vol. 119, no. 2, pp. 455–463, 2007.

[22] I. Sinha, A. L. Pusic, E. G. Wilkins et al., “Late surgical-site infection in immediate implant-based breast reconstruction,” Plastic and Reconstructive Surgery, vol. 139, no. 1, pp. 20–28, 2017.

[23] A. K. Alderman, E. G. Wilkins, H. M. Kim, and J. C. Lowery, “Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study,” Plastic and Reconstructive Surgery, vol. 109, no. 7, pp. 2265–2274, 2002.

[24] J. J. Disa, D. D. Ad-El, S. M. Cohen, P. G. Cordeiro, and D. A. Hidalgo, “The premature removal of tissue expanders in breast reconstruction,” Plastic and Reconstructive Surgery, vol. 104, no. 6, pp. 1662–1665, 1999.

[25] C. N. Stewart, B. B. Liu, E. E. Zheng, and S.–M. C. Tuttle, ”Peri-prosthetic fluid analysis in the diagnosis of breast implant infections using cell count and differential,” Aesthetic Surgery Journal Open Forum, vol. 2, no. 3, 2020.